Skip to content

Comparison of ropivacaine combined with different adjuvants in nerve block in orthopedic foot and ankle surgery

Comparison of ropivacaine combined with different adjuvants in nerve block in orthopedic foot and ankle surgery

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048127
Enrollment
Unknown
Registered
2021-07-03
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

foot and ankle surgery

Interventions

Experimental group 1:10mg dexamethasone and 0.375% ropivacaine for 30ml
Experimental group 2:A total of 0.75µg/kg dexmedetomidine and 0.375% ropivacaine were 30ml
Control group:0.375% ropivacaine 30ml

Sponsors

Beijing Tongren Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 to 75 years who are going to undergo elective ankle surgery under general anesthesia in Beijing Tongren Hospital; 2.ASA 1-3 subjects; 3.For subjects who underwent single foot surgery, the estimated operation time was 0-3 hours; 4.Subjects with BMI 18-30 kg / m^2; 5.The subjects who agreed to participate in this study and signed the informed consent before operation.

Exclusion criteria

Exclusion criteria: 1.Subjects with contraindications to anesthesia (coagulation disorder, puncture site infection, allergy to general or local anesthetics); 2.Subjects with predictable difficult airway; 3.Subjects with central or peripheral neuropathy; 4.Pregnant women and lactating women; 5.Patients with long-term opioid use; 6.Patients with abnormal liver and kidney function: ALT and / or AST > 2 x ULN, or TBIL >= 1.5 x ULN; Serum creatinine > 112 µmol/L, Or received dialysis treatment within 28 days before operation; 7.Patients with diabetes who were not satisfactorily controlled (fasting glucose >= 11mmol/L) during screening period; 8.Subjects who participated in other clinical trials within 30 days; 9.Patients with tumor; 10.Patients with Charcot osteoarthropathy; 11.Patients with a long history of hormone use.

Design outcomes

Primary

MeasureTime frame
Time of first onset of pain;

Secondary

MeasureTime frame
Pain score at each time point;Opioid side effects;Bradycardia occurred during surgery;Patient satisfaction;Complications associated with nerve block;Hypotension;Total opioid consumption;Time to first request analgesia;

Countries

China

Contacts

Public ContactWang Guyan

Beijing Tongren Hospital Affiliated to Capital Medical University

guyanwang2006@163.com+86 13910985139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026